Drug Trial Radar · NCT05084638
Study to Assess the Effect of Ofatumumab in Treatment Naïve, Very Early RRMS Patients Benchmarked Against Healthy Controls.
Last checked: Nov 20, 2026Latest source record: Feb 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
180
Actual
Start
Jan 25, 2022
Primary completion
Feb 4, 2025
Study completion Feb 11, 2026
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Oct 20, 2021
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 35 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This study evaluates the impact of ofatumumab in Relapsing Remitting Multiple Sclerosis (RRMS) participants that are very early in the course of their disease using clinical and magnetic resonance imaging (MRI) outcomes. The study also assesses changes in disease using monitoring techniques including digital biometric device use, biomarker analysis and non-conventional MRI. Select outcomes in the ofatumumab treated group will be compared to a group of Healthy participants to determine if there are similarities between the groups after the patients with MS undergo treatment with ofatumumab.
Conditions
- Relapse Remitting Multiple Sclerosis
Interventions
OfatumumabDrug
20mg subcutaneous injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants Achieving NEDA-3 (No Evidence of Disease Activity-3)Time frame: Month 6 to month 18
Locations
36 sites in 2 countries. Site status is shown where the registry gives one.
MD First Research
Chandler, Arizona
Barrow Neurological Clinics at St Josephs Hospital and MC
Phoenix, Arizona
Arizona Neuroscience Research LLC
Phoenix, Arizona
Keck School of Medicine
Los Angeles, California
Lundquist Inst BioMed at Harbor
Torrance, California
Regina Berkovich MD PhD Inc
West Hollywood, California
UC Health Neuroscience Ctr
Aurora, Colorado
MedStar Health
Washington D.C., District of Columbia
Neurology of Central FL Res Ctr
Altamonte Springs, Florida
First Choice Neurology
Boca Raton, Florida
University of Florida
Gainesville, Florida
Neurology Associates PA
Maitland, Florida
Orlando Health Clinical Trials
Orlando, Florida
Emerald Coast Neurology
Pensacola, Florida
Tallahassee Neurological Clinic
Tallahassee, Florida
University Of South Florida
Tampa, Florida
Shepherd Center
Atlanta, Georgia
Ochsner Cancer Institute
New Orleans, Louisiana
University of Massachusetts Medical School
Worcester, Massachusetts
Henry Ford Hospital
Detroit, Michigan
Renown Institute for Neurosciences
Reno, Nevada
Neuroscience Institute at Hackensack
Hackensack, New Jersey
University of New Mexico
Albuquerque, New Mexico
Velocity Clinical Research
Raleigh, North Carolina
Neurology Diagnostics Inc
Dayton, Ohio
Multiple Sclerosis Center of Excellence of OMRF
Oklahoma City, Oklahoma
Thomas Jefferson University Hospital
Philadelphia, Pennsylvania
Sibyl Wray MD Neurology PC
Knoxville, Tennessee
Univ of Texas Southwest Med Center
Dallas, Texas
UT Health Science Center
Houston, Texas
Lonestar Neurology of San Antonio
San Antonio, Texas
Evergreen Health Multiple Sclerosis Center
Kirkland, Washington
MultiCare Neuroscience Center of Washington
Tacoma, Washington
West Virginia University Hospital
Morgantown, West Virginia
Medical College of Wisconsin
Milwaukee, Wisconsin
Caribbean Center for Clinical Research, Inc
Guaynabo, Puerto Rico
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.